Globis Capital Partners

Globis Capital Partners is one of Japan’s most established independent venture firms, distinguished by its connection to the Globis business school network and by an unusually hands-on approach for the Japanese market. The Tokyo team operates with a clear preference for companies that intend to compete globally rather than remain domestic champions, and its school network gives it an unusual reach into mid-career operators and executives.

The healthcare focus covers AI/ML in healthcare, health IT and healthcare software, and pharma and therapeutics. The fund is willing to back foundational AI work, software platforms targeting clinical and life-science workflows, and frontier therapeutic companies whose underlying science is differentiated. Japan’s healthcare environment, with its aging population, universal coverage, and historically slow tech adoption, gives the fund a natural domestic test bed for several of these categories, and Globis is candid about helping portfolio companies use that domestic position as a credibility platform for international expansion.

Check sizes run from $5M to $25M, with the fund active across seed, Series A, Series B, and growth rounds. That stage breadth allows Globis to be either a lead in early institutional rounds or a meaningful participant in growth rounds, often alongside global co-investors. Founders should expect the fund to be deliberate in diligence and patient in capital deployment, consistent with Japanese investor norms, but also unusually direct in its operating engagement post-investment.

The team brings a mix of investing, operating, and management consulting backgrounds, with strong ties to Japanese corporates and the Globis MBA community. That network shows up in hiring, customer development, and partnership work for portfolio companies, particularly those that need credibility with Japanese hospital systems, pharmaceutical companies, or regulators. The firm is comfortable working with founders whose first language is not English and whose product roadmaps are designed for Japanese clinical and regulatory contexts.

Working with Globis means an investor that takes governance seriously, expects detailed reporting, and engages actively on strategic questions. Post-investment support tends to focus on commercial introductions inside Japan, hiring senior local talent, and managing the transition from a Japan-centric business to a globally legible one. The fund is willing to be a long-term partner through multiple rounds and is candid about the time horizons that pharma and complex AI companies require. It is a less natural fit for founders who treat Japan as a side market or who want a fast, US-style fundraising process. It is a strong fit for technically credible teams who see Japan as a serious base of operations and who want an investor with deep local relationships and the patience to build international scale on top of a Japanese foundation. Founder communication tends to be measured and substantive rather than transactional.